Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-21Clinical Trial Update: Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib [Phase 4]
A Phase 4 clinical trial evaluating surgical or radiotherapeutic intervention for large singular metastases in BRAFV600-mutated melanoma pat…
-
CLINICAL_TRIALS withdrawal · 2026-04-03Clinical Trial Update: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
The ECOG-ACRIN trial assessing biomarker testing practices for common solid cancers in community oncology settings has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-01-02Clinical Trial Update: NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis [Phase 1, Phase 2]
A phase 1/2 trial of NovoTTF-200A in combination with pembrolizumab for metastatic melanoma with brain metastases has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-12-24Clinical Trial Update: STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma [Phase 1]
A Phase 1 study of STIL101 for injection across pancreatic ductal adenocarcinoma, colorectal cancer, renal cell carcinoma, cervical cancer, …
-
CLINICAL_TRIALS withdrawal · 2025-12-18Clinical Trial Update: Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
The compassionate use program for trametinib and dabrafenib in BRAF-mutant metastatic melanoma has ended and is no longer available.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-11-21Clinical Trial Update: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors has been terminated.
-
EMA withdrawal · 2025-10-23EMA Application withdrawn: Amtagvi (lifileucel) — Iovance Biotherapeutics B.V.
EMA has withdrawn the application for Amtagvi (lifileucel) for melanoma.
-
CLINICAL_TRIALS withdrawal · 2025-10-02Clinical Trial Update: Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients [Phase 2, Phase 3]
The phase 2/3 trial of a Modified Melanoma Vaccine for high-risk HLA-A2+ melanoma and metastatic melanoma has been withdrawn.
-
EMA withdrawal · 2025-10-01EMA Application withdrawn: Nidlegy (bifikafusp alfa;onfekafusp alfa) — Philogen S.p.A.
The European Medicines Agency has withdrawn the application for Nidlegy (bifikafusp alfa; onfekafusp alfa) indicated for melanoma, submitted…
-
CLINICAL_TRIALS withdrawal · 2025-09-29Clinical Trial Update: Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma [Phase 2]
A phase 2 trial evaluating pembrolizumab with and without healthy donor FMT plus lenvatinib in relapsed/refractory melanoma has been withdra…
-
CLINICAL_TRIALS withdrawal · 2025-08-07Clinical Trial Update: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung [Phase 1]
A Phase 1 trial evaluating aerosolized sargramostim in combination with immunotherapy for metastatic cutaneous melanoma with lung involvemen…
-
CLINICAL_TRIALS withdrawal · 2025-07-09Clinical Trial Update: Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma [Phase 2]
Phase 2 trial of intravenous iron in combination with standard-of-care immunotherapy for melanoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
A non-interventional pilot study sponsored by ProgenaBiome to explore skin microbiota in skin cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma [Phase 1]
A Phase 1 trial of LN-144 in combination with pembrolizumab for high-risk resectable stage III melanoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-31Clinical Trial Update: Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Expanded access to omaveloxolone for melanoma for patients previously enrolled in trial 408-C-1401 is no longer available.
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases [Phase 1]
A Phase 1 trial of vemurafenib in combination with whole-brain radiation therapy or radiosurgery for patients with BRAF-mutant melanoma and …
-
CLINICAL_TRIALS withdrawal · 2025-02-25Clinical Trial Update: Study of rSIFN-co for Patients With Advanced Solid Tumors [Phase 1]
A Phase 1 clinical trial of rSIFN-co for advanced solid tumors has been terminated, involving malignancies including melanoma, kidney cancer…
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [Phase 1, Phase 2]
The QUILT-3.046 trial evaluating the NANT Melanoma Vaccine in combination immunotherapy for melanoma patients who progressed after chemother…
-
CLINICAL_TRIALS withdrawal · 2024-09-20Clinical Trial Update: Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
The clinical trial evaluating immunogenicity and safety of pneumococcal vaccination in patients treated with immune checkpoint inhibitors fo…
-
EMA withdrawal · 2022-12-15EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.
The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.
-
CLINICAL_TRIALS withdrawal · 2019-01-30Clinical Trial Update: A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma [Phase 1]
A Phase 1 pilot trial evaluating the combination of trientine and vemurafenib for BRAF-mutated metastatic melanoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-18Clinical Trial Update: Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating Glembatumumab Vedotin in combination with nivolumab and ipilimumab for advanced, unresectable solid tu…
-
CLINICAL_TRIALS withdrawal · 2018-07-09Clinical Trial Update: SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
The SPECTAmel trial, which screened melanoma patients to improve access to clinical trials, has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-05Clinical Trial Update: Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy [Phase 1]
A Phase 1 trial evaluating adjuvant oral decitabine and tetrahydrouridine, with or without celecoxib, in patients undergoing pulmonary metas…
-
CLINICAL_TRIALS withdrawal · 2018-05-15Clinical Trial Update: A Clinical Trial of Patients With Melanoma [Phase 1]
A Phase 1 clinical trial for melanoma sponsored by University of Texas Southwestern Medical Center has been withdrawn.